MedTrace Logo

Efficacy of Ramelteon in Adults With Chronic Insomnia

NCT00672724 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1081

Last updated 2012-02-28

No results posted yet for this study

Summary

The purpose of this study is to evaluate subjectively reported treatment effects of ramelteon, once daily (QD), in adults with chronic insomnia.

Conditions

  • Chronic Insomnia

Interventions

DRUG

Ramelteon

Ramelteon 8 mg tablets, taken orally, once daily for up to 2 weeks.

DRUG

Placebo

Ramelteon placebo-matching tablets, taken orally, once daily for up to 2 weeks.

Sponsors & Collaborators

Principal Investigators

  • VP Clinical Science · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-02-28
Primary Completion
2005-08-31
Completion
2005-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00672724 on ClinicalTrials.gov